Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,424.85 162.29 1.00%
S&P 500 1,862.31 19.33 1.05%
NASDAQ 4,086.22 52.06 1.29%
Ticker Volume Price Price Delta
STOXX 50 3,139.26 47.74 1.54%
FTSE 100 6,584.17 42.56 0.65%
DAX 9,317.82 144.11 1.57%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

VANDA PHARMACEUTICALS DEADLINE ALERT: Levi & Korsinsky Notifies Investors With Losses in Vanda Pharmaceuticals, Inc. of Class

VANDA PHARMACEUTICALS DEADLINE ALERT: Levi & Korsinsky Notifies Investors With
Losses in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline
of August 26, 2013 to Seek a Lead Plaintiff Position -- VNDA

NEW YORK, Aug. 14, 2013 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that a
class action lawsuit has been commenced in the United States District Court
for the District of Columbia on behalf of investors who purchased Vanda
Pharmaceuticals, Inc. ("Vanda" or the "Company") (Nasdaq:VNDA) stock between
December 18, 2012 and June 18, 2013.

For more information, click here:

The complaint alleges that defendants violated federal securities laws by
issuing materially false and misleading statements and/or failing to disclose
materially adverse facts concerning the Company's Phase III testing of the
drug Tasimelteon. In particular, it is alleged that, in the middle of the
Phase III studies, Vanda altered the primary endpoint to one never before used
in a sleep-drug clinical trial—and not endorsed by the FDA—when data suggested
the original endpoint would not be met.

On June 19, 2013, an article was published on, questioning the
efficacy of Vanda's study, noting that the study not only changed multiple
times, but that it replaced the primary endpoint just a month before study
results were announced. On the news, shares of Vanda closed at $8.51 per share
on June 19, 2013, a drop of more than 20% from the previous day.

If you suffered a loss in Vanda you have until August 26, 2013 to request that
the Court appoint you as lead plaintiff. Your ability to share in any recovery
doesn't require that you serve as a lead plaintiff. To obtain additional
information, contact Joseph E. Levi, Esq. either via email at or
by telephone at (877) 363-5972, or visit

Levi & Korsinsky is a national firm with offices in New York, New Jersey, and
Washington D.C.  The firm has extensive expertise in prosecuting securities
litigation involving financial fraud, representing investors throughout the
nation in securities and shareholder lawsuits.  Attorney advertising. Prior
results do not guarantee similar outcomes.

CONTACT: Levi & Korsinsky, LLP
         Joseph Levi, Esq.
         Eduard Korsinsky, Esq.
         30 Broad Street - 24th Floor
         New York, NY 10004
         Tel: (212) 363-7500
         Toll Free:  (877) 363-5972
         Fax: (866) 367-6510
Sponsored Links
Sponsored Links